Simplex Trading Adds $1M in Apogee Therapeutics, Inc. ($APGE)
Key Points
- Simplex Trading changed its Apogee Therapeutics, Inc. ($APGE) stake by 23.9% last quarter, boosting to 77,808 shares worth $6.96 million.
- Wall Street's consensus rating on $APGE is Strong Buy and an average price target of $119.50.
- $APGE last traded around $89.50.
Simplex Trading increased its position in Apogee Therapeutics, Inc. ($APGE) by 23.9% during the most recent quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 77,808 shares of Apogee Therapeutics, Inc. after buying 15,009 shares during the quarter. Simplex Trading's holdings in Apogee Therapeutics, Inc. were worth $6.96 million as of its most recent filing.
Apogee Therapeutics, Inc. ($APGE) Stock
Apogee Therapeutics, Inc. Earnings
Analysts Set New Price Targets
About Apogee Therapeutics, Inc.
Apogee Therapeutics, Inc., a clinical stage biotechnology company, develops novel biologics for the treatment of atopic dermatitis, asthma, eosinophilic esophagitis, chronic obstructive pulmonary disease, and other inflammatory and immunology indications in the United States. The company develops Zumilokibart (APG777), a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) for the treatment of atopic dermatitis, which is in phase 2 clinical trials; and for the treatment of asthma and eosinophilic esophagitis which is in phase 1 clinical trial. It also develops APG279 which is in phase 1 clinical trial for the treatment of atopic dermatitis; APG273 which is in phase 1 clinical trial for the treatment of asthma and chronic obstructive pulmonary disease; and APG808, an SQ extended half-life mAb targeting IL-4Ra for the treatment of Type 2 allergic diseases. Apogee Therapeutics, Inc. was incorporated in 2022 and is headquartered in Waltham, Massachusetts.
See Also
This instant news alert was generated by automated narrative technology and financial data from Opentrades and public regulatory filings. It is for informational purposes only and is not financial advice.